Announcements
Projects
Orgs
Project
Articles 130
Votes 0
Endpoints News

Authors 22

Max Gelman
Tyler Patchen
Lei Lei Wu
Amber Tong
John Carroll
Zachary Brennan
Kyle LaHucik
Nicole DeFeudis
Paul Schloesser
Katherine Lewin
Beth Snyder Bulik
Katherine
Andrew Dunn
Drew Armstrong
Ryan Cross
Jared Whitlock
Reynald Castañeda
Jaimy Lee
Ayisha Sharma
Anna Brown
Lia DeGroot
ENDPOINTS
Lilly's diabetes and obesity leader to retire in broader leadership shuffle as CSO Dan Skovronsky takes on immunology role - Endpoints News
~2y
GLP-1 gene therapy triggers 25% weight loss in obese mice, clinical trials planned for next year - Endpoints News
~2y
Updated: Sanofi's $1.5B pact with Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer - Endpoints News
~2y
Novo Nordisk secures FDA approval of RNAi therapy from $3.3B Dicerna takeover - Endpoints News
~2y
FDA unveils new rare disease pilot program to increase agency-sponsor communications - Endpoints News
~2y
FDA approves major depressive drug after rejecting it multiple times in past two decades - Endpoints News
~2y
For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation - Endpoints News
~2y
FDA advisors unanimously reject Intarcia's embattled type 2 diabetes treatment - Endpoints News
~2y
Travere Therapeutics just misses on confirmatory study for kidney disease drug, stock plummets - Endpoints News
~2y
Taysha stops developing a gene therapy amid debate over FDA's stance on ultra-rare trials - Endpoints News
~2y
Lonza CEO Pierre-Alain Ruffieux to leave CDMO amid reduced growth - Endpoints News
>2y
Moderna cuts four programs in vaccines, solid tumors and heart failure as it increases, prioritizes pipeline - Endpoints News
>2y
FDA adcomm votes in favor of Alnylam's new indication for Onpattro - Endpoints News
>2y
Moderna strikes $1.8B cancer research deal with Immatics - Endpoints News
>2y
NASH company Madrigal names former Sanofi exec Bill Sibold as new CEO - Endpoints News
>2y
MIT scientists tweak mRNA Covid jabs to be ‘self-adjuvanting’ - Endpoints News
>2y
Pfizer expects fewer people needed for Lyme disease vaccine trial - Endpoints News
>2y
FDA puts partial hold on Gilead's CD47 hopeful in AML - Endpoints News
>2y
Alaunos' runway ends before New Year's, as TCR biotech shrinks staff, seeks sale - Endpoints News
>2y
Covid companies cut costs as boom recedes from vaccines and drugs - Endpoints News
>2y
Novo Nordisk snaps up Inversago Pharma for up to $1B+ on the back of megablockbuster Wegovy sales - Endpoints News
>2y
Vistagen's positive PhIII for social anxiety nasal spray pushes stock price up 1000+% - Endpoints News
>2y
AstraZeneca picks up Pfizer's rare disease gene therapies, taps new R&D leader as Mene Pangalos steps down - Endpoints News
>2y
Revlimid losses lead Bristol Myers Squibb to lower full-year guidance - Endpoints News
>2y
NASH or MASH? Name changes to established condition stir up confusion in liver disease community - Endpoints News
>2y